Novo Holdings A/S said Monday that it has completed its $16.5 billion all-cash acquisition of Catalent (CTLT, Financials). Catalent will be privately held by Danish life sciences investment business Novo Holdings and provide pharmaceutical and biotechnology services worldwide.
Reflecting a 47.5% premium over the 60-day volume-weighted average price as of Feb. 2, the contract entitites Catalent stockholders to receive $63.50 per share in cash. Catalent's common stock stopped trading and was dropped from the New York Stock Exchange after the purchase.
Alessandro Maselli, the President and CEO of Catalent, will continue in that capacity. Maselli said in a statement that the purchase marks a "significant milestone" for the business as Novo Holdings's backing of Catalent would enable it to better serve consumers and patients, therefore creating value for stakeholders.
Emphasizing the company's vital contribution to the pharmaceutical, biotechnology, and consumer health industries, Novo Holdings CEO Kasim Kutay welcomed Catalent's team into the portfolio of the investment business Kutay showed faith in Catalent's ability for further expansion and fit with Novo Holdings' goal of helping people and the earth.
Senior Partner Jonathan Levy of Novo Holdings also pointed out that the company wants to increase Catalent's operational momentum and worldwide influence.
Shortly after the closing of the agreement, Novo Nordisk A/S will purchase three Catalent fill-finish plants from Novo Holdings. Located in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium, the facilities include connected assets vital for the operations of the business.
